Free Access
Issue
J Extra Corpor Technol
Volume 46, Number 1, March 2014
Page(s) 94 - 97
DOI https://doi.org/10.1051/ject/201446094
Published online 15 March 2014
  1. Poncz M. Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg. 2005;17:73–79. [CrossRef] [Google Scholar]
  2. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: A review. Chest. 2004;126:249–258. [CrossRef] [PubMed] [Google Scholar]
  3. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology. 2005;102:276–284. [CrossRef] [PubMed] [Google Scholar]
  4. Zulys VJ, Teasdale SJ, Michel ER, et al. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989;71:870–877. [CrossRef] [PubMed] [Google Scholar]
  5. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparinassociated thrombocytopenia. Chest. 1999;115:1616–1620. [CrossRef] [PubMed] [Google Scholar]
  6. Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Thorac Surg. 2007;84:836–839. [CrossRef] [Google Scholar]
  7. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON Trial. Ann Thorac Surg. 2007;83:572–577. [CrossRef] [Google Scholar]
  8. Zamora R. Successful anticoagulation with bivalirudin in antithrombin deficient pediatric patient undergoing stent placement. Catheter Cardiovasc Interv. 2006;68:292–295. [CrossRef] [PubMed] [Google Scholar]
  9. Pieri M, Agracheva N, Bonaveglio E, et al. Bivalirudin versus heparinas an anticoagulant during extracorporeal membrane oxygenation: A case–control study. J Cardiothorac Vasc Anesth. 2013;27:30–34. [CrossRef] [Google Scholar]
  10. Koster A, Weng Y, Bottcher W, et al. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83:1865–1867. [CrossRef] [Google Scholar]
  11. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96:383–386. [Google Scholar]
  12. Salemi A, Agrawal YP, Fontes MA. An assay to monitor bivalirudin levels on cardiopulmonary bypass. Ann Thorac Surg. 2011;92:332–334. [CrossRef] [Google Scholar]
  13. Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275. [CrossRef] [PubMed] [Google Scholar]
  14. Ranucci M. Bivalirudin and post-cardiotomy ECMO: A word of caution. Crit Care. 2012;16:427–. [CrossRef] [PubMed] [Google Scholar]
  15. Mateen FJ, Muralidharan R, Shinohara RT, et al. Neurological injury in adults treated with extracorporeal membrane oxygenation. Arch Neurol. 2011;68:1543–1549. [CrossRef] [PubMed] [Google Scholar]
  16. Polito A, Barrett CS, Wypij D, et al. Neurologic complications in neonates supported with extracorporeal membrane oxygenation. An analysis of ELSO registry data. Intensive Care Med. 2013;39:1594–1601. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.